Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
Type:
Application
Filed:
February 25, 2021
Publication date:
January 20, 2022
Applicants:
Acceleron Pharma Inc., Ludwig Institute for Cancer Research Ltd.
Inventors:
Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
Abstract: In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer.
Type:
Grant
Filed:
May 28, 2019
Date of Patent:
December 28, 2021
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne Sako
Abstract: In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides T?RII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.
Type:
Grant
Filed:
December 14, 2017
Date of Patent:
December 21, 2021
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Rajasekhar Naga Venkata Sai Suragani
Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
Type:
Application
Filed:
January 4, 2021
Publication date:
December 16, 2021
Applicants:
Ludwig Institute for Cancer Research Ltd., Acceleron Pharma, Inc.
Inventors:
Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Type:
Grant
Filed:
February 19, 2020
Date of Patent:
November 9, 2021
Assignee:
ACCELERON PHARMA INC.
Inventors:
Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Type:
Grant
Filed:
March 3, 2020
Date of Patent:
November 2, 2021
Assignee:
ACCELERON PHARMA INC.
Inventors:
Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Type:
Grant
Filed:
February 19, 2020
Date of Patent:
October 26, 2021
Assignee:
ACCELERON PHARMA INC.
Inventors:
Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
Type:
Application
Filed:
June 4, 2021
Publication date:
September 30, 2021
Applicants:
Acceleron Pharma Inc., Acceleron Pharma Inc.
Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.
Type:
Application
Filed:
March 18, 2021
Publication date:
September 30, 2021
Applicant:
Acceleron Pharma Inc.
Inventors:
Asya Grinberg, Roselyne Castonguay, Eric Werner, Ravindra Kumar
Abstract: In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in a subject in need thereof. Subjects in need include, for example, subjects having anemia and/or ineffective erythropoiesis as a result of having reduced GATA-1, heat shock factor and/or NFE2 levels as compared to the levels in a reference population.
Type:
Grant
Filed:
November 4, 2016
Date of Patent:
September 21, 2021
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Pedro Martinez, Naga Venkata Sai Rajasekhar Suragani
Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.
Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
Type:
Grant
Filed:
November 26, 2019
Date of Patent:
July 13, 2021
Assignee:
Acceleron Pharma Inc.
Inventors:
John Knopf, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Asya Grinberg, Dianne Sako, Roselyne Castonguay, Yossi Dagon
Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
Type:
Grant
Filed:
January 18, 2019
Date of Patent:
June 8, 2021
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay, Gang Li, Yossi Dagon, John Knopf
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Type:
Grant
Filed:
February 19, 2020
Date of Patent:
June 8, 2021
Assignee:
ACCELERON PHARMA INC.
Inventors:
Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Type:
Grant
Filed:
March 3, 2020
Date of Patent:
June 8, 2021
Assignee:
ACCELERON PHARMA INC.
Inventors:
Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
Abstract: In certain aspects, the present disclosure relates to T?RII fusion polypeptides comprising a heterologous portion and a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
Type:
Grant
Filed:
January 30, 2020
Date of Patent:
May 18, 2021
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves